Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
This "Boring" Pipeline Stock Has Never Cut Its Dividend. Here's the 1 Number I'd Watch.
This pipeline MLP's approach to cash flow distribution is key to its dividend growth streak.
What's Going on with SpaceX Stock?
SpaceX stock is caught between a gigantic opportunity and gigantic expectations.
Tinubu’s fuel subsidy gamble: Nigerians paid the tax price, now Atiku offers a way
Nigeria does not need a return to the corrupt subsidy regime of the past. It needs a production-based subsidy that read more Tinubu’s fuel subsidy gamble: Nigerians paid the tax price, now Atiku…
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
WHERE TO INVEST: Inside the mind of Redefine: A bold Poland push and a lesson in active asset management
The property group balances South African retail, industrial and office plays with more exposure in Poland, using refurbishments and developments to unlock capital upside and protect dividends.
Banque Misr UAE branches to continue normal operations, central banks say
Dubai: Banque Misr’s branches in the UAE will continue to conduct all their operations normally, the UAE and Egyptian central banks said on Sunday, following a US Treasury decision concerning the…